ICON plc | Clinical Research Organisation (CRO) for Drug Development

Medical communications in early phase product development

A step-by-step guide to creating market success.

Long-term follow-up studies of cell and gene therapies

Success factors related to conducting basket LTFU studies.

wearables smart watch connected for digital health technologies

Closing the evidence gap

The value of digital health technologies in supporting drug reimbursement decisions

Understanding the Periodic Benefit-Risk Evaluation Report

How careful preparation of the initial PBRER sets up future success.

Webinars

Upcoming webinar: Qualitative longitudinal research in patient-centred research

8 February 2022 - Register now

Upcoming webinar: Tools of the trade for patient-centric clinical development

23 February 2022 - Register now

On-demand webinars

Visit our webinar channel to access other recent webinars.

Featured Services

Seeking parallel consultation from regulators and HTA bodies in Europe

Market Access

Expertise in mission-critical pricing, market access, and reimbursement.�

Site & Patient Solutions

Transforming recruitment through patient-centric trials and real-world, real-time data.

Biotech

ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation.

Functional Resourcing

From recruitment of a single clinical professional to managing entire global functions.

Increasing Site and Patient Compliance

FIRECREST: Digital solutions to increase efficiency in clinical trials by driving site performance.

ICON Insights

25 January 2022

Progressive IVDR rollout made official

In the fall of 2020, the European Commission issued a proposal to modify the implementation timeline for the new In Vitro Diagnostic Medical Devices Regulation (IVDR). Now, as of 15 December 2021, the European Parliament and the European Council have adopted this proposal, making the suggested progressive IVDR rollout timeline official.

07 January 2022

Combatting AMR with new tools to diagnose and treat infectious disease

The employment of antimicrobials to fight previously devastating microbial diseases, such as tuberculosis, meningitis and pneumonia has been a transformative medical achievement.

07 December 2021

Camaraderie and collaboration – what sets ICON apart

ICON was recently named one of the World’s Best Employers for 2021 by global media company Forbes. This recognition is solely the result of employees’ on-the-job experiences and firsthand feedback.

10 November 2021

EC proposes extended transition period for IVDR compliance

The European Commission has issued a proposal for a modified rollout of the new In Vitro Diagnostic Regulation (IVDR).

01 November 2021

Diverse clinical research starts with the healthcare workforce

Diversity initiatives are a hallmark of clinical research. From US Food and Drug Administration (FDA)-penned guidance and pharma initiatives.

31 October 2021

How we can continue building a diverse, equal, and inclusive industry

Workplace diversity encourages collaboration and innovation – every team member brings their own unique backgrounds, experiences, and perspectives at ICON.

26 October 2021

Navigating cardiovascular clinical trial adjudication during a respiratory pandemic

COVID-19 disrupted clinical trials across all indications. Patient enrolment, participation, data collection, and more was forced to adapt to the challenges of this virus.

19 October 2021

The impact of the COVID-19 pandemic on mental health

Learn how the ongoing state of the COVID-19 pandemic has affected the global mental health crisis.

01 October 2021

ICON Joins UNICEF Corporate Vaccine Alliance

ICON is one of seven leading Irish companies that just endorsed an open letter urging fellow corporate leaders to join the UNICEF Corporate Vaccine Alliance.

Services

Sectors

Therapeutics

Innovation

Insights

News & Events

About ICON

Regulatory considerations for biotech

Spotlight on regulatory reforms in China

Diversity and inclusion in clinical trials

Practical considerations for decentralised & hybrid clinical trials